Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology. - Wikidata - wikimedia - TriplyDB

Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.

Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.

http://www.wikidata.org/entity/Q33228693

about

High drug-loading nanomedicines: progress, current status, and prospects.Nanosuspension: An approach to enhance solubility of drugs The nanoscale in pulmonary delivery. Part 2: formulation platforms.Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods.Loco-regional administration of nanomedicines for the treatment of lung cancer.In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone.Generation of TiO2 Aerosols from Liquid Suspensions: Influence of Colloid Characteristics Nanosuspension Technologies for Delivery of Poorly Soluble Drugs

P2860

Q33766568-A8034D98-8A0C-4046-8C90-3E4304E85191 Q35554511-8E97A425-81DC-400F-AFB3-80E0C7F2E160 Q36985898-E57D60B1-4D1E-4B0A-ACBB-CA1DEBB3A820 Q37805588-1FC2D4CA-9DFB-4641-9A80-EDBBFC5FE425 Q38639228-80FAEA32-38F3-4D99-AE2B-8846901F6E82 Q43171576-E9379015-535B-46F9-BD62-221C23CE90C6 Q58144090-EA2D3C73-6E2D-4B02-AAFB-2E6CB7E97817 Q59113220-67337A1C-A1E1-43F6-A8E0-42302E3776C2

P2860

Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.

http://www.wikidata.org/entity/Q33228693

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Characterization of nebulized ...... ct of nebulization technology.

@ast

Characterization of nebulized ...... ct of nebulization technology.

@en

type

label

Characterization of nebulized ...... ct of nebulization technology.

@ast

Characterization of nebulized ...... ct of nebulization technology.

@en

prefLabel

Characterization of nebulized ...... ct of nebulization technology.

@ast

Characterization of nebulized ...... ct of nebulization technology.

@en

P1433

Q33228693-9CB6721D-0393-4469-B11E-9974746A085E

P1476

Q33228693-339695C1-2D47-47A6-8A39-4C81DDCDA67C

P2093

Q33228693-01301004-5252-4B03-966E-3368B05C13CB

Q33228693-6BE875AD-BA84-4B7B-A714-E0EE3C76CC85

Q33228693-DB7415D8-5EEE-49AE-8B21-D866561C0657

P2860

Q33228693-183741D8-DDEA-4FD5-A442-DA9D0E140E98

Q33228693-1AC59A2C-53B3-4D46-BE92-36B5130E4295

Q33228693-221B9F40-AE7E-4981-A6FB-EDFB049C66EA

Q33228693-300CA8DC-9564-4DE5-AC31-90524943832F

Q33228693-8824B0EE-13C6-4312-9367-5D412EDCA1E9

Q33228693-8944FF48-2699-4DF3-9CA2-4E06D05E5345

Q33228693-9194C211-8B2E-4792-BDBC-02B8BAD37E2D

Q33228693-97C83F00-6FDA-4EB1-802D-DD8919F846E9

Q33228693-AF01BFD9-1D8D-481D-9891-0E5D0EC4E1DF

Q33228693-E6F92B9A-8758-42A8-A549-9DABFEA19CFF

P304

Q33228693-B4237005-7BD6-46BE-B8F7-0FE622E9AB38

P31

Q33228693-C736D698-5BE2-4948-873A-A9A2FBB46D2F

P356

Q33228693-A9BF85BA-5B0D-490E-BCDA-BD8C9EF4818B

P433

Q33228693-0001D430-94AC-4389-92E6-C107000F56AD

P478

Q33228693-377B6CC7-9C15-4405-8981-81901DCE97C7

P50

Q33228693-75107FED-9D9E-424F-9CDE-0FC36E53C501

P577

Q33228693-DFD1B579-6C6D-4310-B244-C49DBA612FE6

P5875

Q33228693-B0A702F5-A1B6-455E-A1F1-29B6CB434A42

P698

Q33228693-D34B723D-B609-4A63-BA65-C4E67AF49EF9

P356

10611860500353245

P1433

Journal of Drug Targeting

P1476

Characterization of nebulized ...... ct of nebulization technology.

@en

P2093

Hartwig Steckel

http://www.w3.org/2001/XMLSchema#string

Norma Hernández-Trejo

http://www.w3.org/2001/XMLSchema#string

Rainer H Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides

Selective deposition of inhaled aerosols to mechanically ventilated rabbits.

Production and characterization of a budesonide nanosuspension for pulmonary administration.

Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients.

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

Pneumocystis carinii.

Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers.

Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.

Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers.

P304

499-507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10611860500353245

http://www.w3.org/2001/XMLSchema#string

P433

8-9

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7436208

http://www.w3.org/2001/XMLSchema#string

P698

16332575

http://www.w3.org/2001/XMLSchema#string